FORA Capital’s Agios Pharmaceuticals AGIO Stock Holding History

FORA Capital’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-5,515	Closed	-$295K	–	629
2020 Q2	$295K	Buy	+5,515	New	+$255K	0.1%	258

Other funds holding AGIO

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FORA Capital's AGIO Position: Q3 2020 in Review

FORA Capital sold out of Agios Pharmaceuticals (AGIO) in Q3 2020, closing a stake of 5,515 shares — an estimated $295K sold.

FORA Capital first reported a position in AGIO in Q2 2020 and held it in 1 quarter. The position peaked at $295K in Q2 2020. 214 funds tracked by Wall St. Rank hold AGIO as of Q3 2020.

FORA Capital reported no remaining Agios Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
FORA Capital sold 5,515 Agios Pharmaceuticals shares in Q3 2020, an estimated $295K.
FORA Capital first reported a position in Agios Pharmaceuticals in Q2 2020 and held it in 1 quarter.
FORA Capital's Agios Pharmaceuticals position peaked at $295K in Q2 2020.
214 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2020.

Based on FORA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.